AVA Bio Defender

Company Overview

Snapshot

Founded in January 2007 by Lior Zigler, AVA Bio Defender operates with 1–10 employees. The company has raised $2.5 million across one funding round, demonstrating early investor confidence in its biotechnology advancements. AVA Bio Defender is currently in the clinical trial phase for its product development.

Business overview

AVA Bio Defender is a biotechnology company focused on developing mutation-resistant viral defense mechanisms. The company utilizes siRNA technology to create a gene-delivery system for antiviral protection in animals, particularly poultry, and employs CRISPR technology for directed genome editing. For human therapy, AVA Bio Defender develops molecules designed to treat infected individuals regardless of viral mutations. Its technologies aim to provide inherent resistance to future viral mutations in animals and effective medicines for humans, operating within the Pharmaceuticals and Drug Delivery sectors.

Company Intelligence Q&A

What is AVA Bio Defender's primary focus?

AVA Bio Defender specializes in developing mutation-resistant viral defense technologies for both animal health and human therapy, utilizing advanced genetic engineering techniques.

When was AVA Bio Defender founded?

AVA Bio Defender was founded in January 2007.

Who is the founder of AVA Bio Defender?

Lior Zigler is the Founder and CEO of AVA Bio Defender.

What technologies does AVA Bio Defender use?

AVA Bio Defender employs siRNA technology for gene-delivery systems in animals and CRISPR technology for directed editing of target genomes. For human therapy, the company develops molecules to treat viral infections.

What is AVA Bio Defender's current product stage?

AVA Bio Defender's products are currently in the Clinical Trial stage, focusing on developing heritable genetic resistance in animals and drug design for human therapy.